12:00 AM
 | 
Aug 10, 2009
 |  BioCentury  |  Regulation

"More is better": ViroPharma's ups and downs

"More is better": ViroPharma's ups and downs

ViroPharma Inc.'s investors have had a bumpy ride since the company received an FDA not-approvable letter for its common cold treatment, pleconaril, in 2002. The stock rebounded to about $22 in February 2006, gaining nearly 1,000% after the company received U.S. rights in 2004 to antibiotic Vancocin Pulvules from Eli Lilly and Co. (NYSE:LLY). The shares fell in March 2006 on concerns that FDA's Office of Generic Drugs would relax requirements for approval of generic versions.More than three years later, ViroPharma (NASDAQ:VPHM) was off 2% last week after an FDA panel voted 17-0 in favor of accepting the agency's recommendation that...

Read the full 529 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >